Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Marinus Pharmaceuticals Inc (MRNS): Are Hedge Funds Right About This Stock?

Page 1 of 2

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at Marinus Pharmaceuticals Inc (NASDAQ:MRNS) from the perspective of those elite funds.

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has experienced an increase in hedge fund interest in recent months. MRNS was in 7 hedge funds’ portfolios at the end of the third quarter of 2015. There were 3 hedge funds in our database with MRNS holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Pure Cycle Corporation (NASDAQ:PCYO), Energy Focus Inc (PINK:EFOI), and TRACON Pharmaceuticals Inc (NASDAQ:TCON) to gather more data points.

Follow Marinus Pharmaceuticals Inc (NASDAQ:MRNS)
Trade (NASDAQ:MRNS) Now!

Keeping this in mind, we’re going to view the recent action encompassing Marinus Pharmaceuticals Inc (NASDAQ:MRNS).

Hedge fund activity in Marinus Pharmaceuticals Inc (NASDAQ:MRNS)

At the end of the third quarter, a total of 7 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 133% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of notable hedge fund managers who were boosting their stakes substantially (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Steve Cohen’s Point72 Asset Management has the largest position in Marinus Pharmaceuticals Inc (NASDAQ:MRNS), worth close to $1.9 million, amounting to less than 0.1% of its total 13F portfolio. On Point72 Asset Management’s heels is Julian Baker and Felix Baker of Baker Bros. Advisors, with a $1.7 million position; less than 0.1% of its 13F portfolio is allocated to the stock. Some other peers with similar optimism consist of Stuart Weisbrod’s Iguana Healthcare Management, William Leland Edwards’s Palo Alto Investors and Nathan Fischel’s DAFNA Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!